[1]荆冠军,赵一鉴△.阿帕替尼治疗晚期肺癌对患者血清肿瘤标志物的影响研究[J].陕西医学杂志,2020,49(10):1351-1355.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.040]
　JING Guanjun,ZHAO Yijian..Effect of apatinib on serum tumor markers in patients with advanced lung cancer[J].,2020,49(10):1351-1355.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.040]
点击复制

阿帕替尼治疗晚期肺癌对患者血清肿瘤标志物的影响研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年10期
页码:
1351-1355
栏目:
临床检验
出版日期:
2020-10-05

文章信息/Info

Title:
Effect of apatinib on serum tumor markers in patients with advanced lung cancer
作者:
荆冠军; 赵一鉴△
陕西省商洛市中心医院(商洛 726000)
Author(s):
JING Guanjun; ZHAO Yijian.
Shangluo Central Hospital,Shaanxi Province(Shangluo 726000)
关键词:
阿帕替尼;  肺癌;  肿瘤标志物;  敏感度;  客观缓解率;  疾病控制率
Keywords:
Apatinib;  Lung cancer;  Tumor markers;  Sensitivity;  Objective remission rate;  Disease control rate
分类号:
R734.2
DOI:
DOI:10.3969/j.issn.1000-7377.2020.10.040
文献标志码:
A
摘要:
目的:探讨阿帕替尼对晚期肺癌患者血清肿瘤标志物癌胚抗原(CEA)、糖抗原125(CA125)、神经元特异性烯醇化酶(NSE)、鳞状细胞癌抗原(SCC)、细胞角蛋白19片段(CyFRA21-1)的影响。方法:选择82例初诊并确诊为肺癌晚期患者作为研究组,选择同期75例肺部良性疾病的患者作为肺疾病良性组,同期80例健康的体检者作为健康组。测定其值采用相对应的试剂盒及全自动化学发光免疫分析仪,比较并分析阿帕替尼治疗前后对血清肿瘤标志物的影响及临床应用价值。结果:肺癌组各肿瘤标志物均显著高于健康组、肺疾病良性组,比较差异有统计学意义(P<0.05); 在不同的治疗时间段,患者血清肿瘤标志物均有降低,在治疗4个月后,与健康组相比,肺癌患者血清的CEA、 CA125、 SCC值差异无统计学意义,但与肺癌组比较差异有统计学意义(P<0.05); 5种血清肿瘤标志物联合后,敏感度显著高于单一检测的肿瘤标志物(P<0.05); 阿帕替尼治疗肺癌患者结束后,ORR(客观缓解率)达到17.07%,DCR(疾病控制率)达到53.66%,总生存时间(OS)超过6个月。结论:阿帕替尼可有效的缓解肺癌患者血清肿瘤标志物,为治疗肺癌晚期患者提供了一定的临床依据。
Abstract:
Objective:To investigate the effect of apatinib on serum tumor markers carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),neuron specific enolase(NSE),squamous cell carcinoma antigen(SCC)and cytokeratin 19 fragment(CYFRA21-1)in patients with advanced lung cancer.Methods:82 patients with advanced lung cancer were selected as research group,and 75 patients with benign lung disease were selected as benign group,and 80 healthy people were selected as healthy group.The corresponding kits and full-automatic chemiluminescence immunoassay instrument were used to compare and analyze the effect of apatinib on serum tumor markers before and after treatment and its clinical application value.Results:The tumor markers in research group were significantly higher than those in healthy group and benign group(P<0.05).In different treatment periods,serum tumor markers of patients were decreased.After 4 months of treatment,there was significant difference in serum CEA,CA125,SCC between research group and healthy group.After combination of five serum tumor markers,the sensitivity was significantly higher than that of single detection tumor marker(P<0.05).After the end of apatinib treatment of lung cancer patients,objective remission rate(ORR)reached 17.07%,disease control rate(DCR)reached 53.66%,and the overall survival time(OS)exceeded six months.Conclusion:Apatinib can effectively alleviate the serum tumor markers in patients with lung cancer,which provides a certain clinical basis for the treatment of patients with advanced lung cancer.

参考文献/References:

[1] 李超群,王秀明,朱凌燕.阿帕替尼治疗12例晚期肺癌的近期疗效评价[J].中国医药导报,2019,16(17):137-139.
[2] Pirker R.Editorial:Individualizing treatment of nonsmall cell lung cancer[J].Current Opinion in Oncology,2020,32(1):35-36.
[3] 丛日楠,谷 芳,王 冰.吉非替尼、厄洛替尼与埃克替尼治疗EGFR基因敏感突变晚期NSCLC患者的疗效观察[J].现代肿瘤医学,2018,26(2):216-219.
[4] 杜建飞,胡海峰.三维适形放疗同步多西他赛周方案化疗治疗老年局部晚期非小细胞肺癌的临床效果评价[J].中国实用医药,2016,11(20):176-177.
[5] Rosell R,Karachaliou N,Arrieta O.Novel molecular targets for the treatment of lung cancer[J].Current Opinion in Oncology,2020,32(1):37-43.
[6] 叶鹏飞,韩星敏,谢新立,等.纵隔淋巴结与原发灶最大标准摄取值比值对非小细胞肺癌纵隔淋巴结转移的诊断价值[J].中国医学影像技术,2014,30(12):1839-1843.
[7] 王 媛,张华丽.肿瘤标志物CEA、NSE、CA125、Pro GRP在肺癌诊断中的价值[J].陕西医学杂志,2016,45(1):14-15.
[8] Zhang JJ,Kulkarni HR,Singh A,et al.Complete regression of lung metastases in a patient with metastatic castration-resistant prostate cancer using 177Lu-PSMA radioligand therapy[J].Clinical Nuclear Medicine,2020,45(1):48-50.
[9] Huang L,Qiao GL,Morse MHA,et al.Predictive significance of T cell subset changes during ex vivo generation of adoptive cellular therapy products for the treatment of advanced non-small cell lung cancer[J].Oncology Letters,2019,18(6):5717-5724.
[10] Van MJP,De PC,Raskin J,et al.Local treatment of stage ⅢA-N2 nonsmall cell lung cancer:surgery and/or radiotherapy[J].Current Opinion in Oncology,2020,32(1):54-62.
[11] 改 丽,李 旭,黄尚科,等.阿帕替尼联合顺铂对食管癌ECA109细胞抑制作用及机制探讨[J].陕西医学杂志,2017,46(2):148-151.
[12] Kosuke H,Kyoichi K,Tomonori K,et al.Psuedoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer[J].Lung Cancer,2019,139(25):221-223.
[13] Tejas P,Rao M,Sydney M,et al.Clinicopathologic characteristics,treatment outcomes,and acquired resistance patterns of atypical egfr mutations and HER2 alterations in stage iv non-small-cell lung cancer[J].Clinical Lung Cancer,2019,14(15):468-474.
[14] Tomoya T,Shinya N,Miku K,et al.Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells[J].International Journal of Pharmaceutics,2019,572(10):117-119.
[15] Daniel M,Manjusha H,William K,et al.Development,validation and results from the impact of treatment evolution in non-small cell lung cancer(iTEN)model[J].Lung Cancer,2020,139(10):185-194.
[16] Meilin J,Enxia Z,Ze L,et al.Liposome-based co-delivery of 7-O-geranyl-quercetin and IGF-1R siRNA for the synergistic treatment of non-small cell lung cancer[J].Journal of Drug Delivery Science and Technology,2019,10(54):49-54.
[17] She LJ,Hu HB,Liao MT,et al.Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater[J].Lung Cancer,2019,138(17):88-94.
[18] 王 玲,申 鸿.癌胚抗原、糖类抗原、CA125、血管生成素、细胞角蛋白19片段及甲胎蛋白检测在肺癌诊断中的临床研究[J].陕西医学杂志,2019,48(8):1080-1084.

相似文献/References:

[1]陈正浤,雷光焰△,韩 乐,等.三氧化二砷抑制人肺癌细胞NCI-H460增殖并促进其凋亡实验研究*[J].陕西医学杂志,2020,49(10):1219.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.005]
[2]何建春,李煜华.纵隔型肺癌MRI、CT影像学特征及诊断价值对比研究*[J].陕西医学杂志,2020,49(10):1232.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.008]
　HE Jianchun,LI Yuhua..Comparative study on MRI and CT features and diagnostic value for mediastinal lung cancer[J].,2020,49(10):1232.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.008]
[3]张 珊,任小平,田应选.老年肺癌患者心理痛苦现状调查及影响因素分析[J].陕西医学杂志,2021,50(2):245.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.030]
　ZHANG Shan,REN Xiaoping,TIAN Yingxuan.Investigation on psychological distress status of elderly patients with lung cancerand analysis of its influencing factors[J].,2021,50(10):245.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.030]
[4]刘振宇,王宏伟.小鼠原位肺癌模型构建及在放射治疗研究中的意义[J].陕西医学杂志,2022,51(7):791.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.005]
　LIU Zhenyu,WANG Hongwei.Establishment of mouse model of lung cancer in situ and its significance in study of radiation therapy research[J].,2022,51(10):791.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.005]
[5]刘 丽,武愫斌.双氧化酶成熟因子2基因检测在肺癌患者淋巴结转移及预后预测中的价值研究[J].陕西医学杂志,2022,51(8):1029.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.029]
　LIU Li,WU Subin.Value of DUOXA2 level in predicting lymph node metastasis and prognosis of lung cancer patients[J].,2022,51(10):1029.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.029]
[6]代 佳,李 林,贺 林,等.中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值与肺癌早期诊断以及临床病理特征相关性分析[J].陕西医学杂志,2023,52(4):468.[doi:DOI:10.3969/j.issn.1000-7377.2023.04.024]
[7]王松海,凡 瑾,陈 捷.红景天苷对Lewis 肺癌小鼠恶性胸腔积液的抑制作用及其对免疫功能的影响[J].陕西医学杂志,2024,(1):37.[doi:DOI:10.3969/j.issn.1000-7377.2024.01.008]
　WANG Songhai,FAN Jin,CHEN Jie.Inhibitory effect of SALidroside on malignant pleural effusion and its effect on immune function in mice with Lewis lung cancer[J].,2024,(10):37.[doi:DOI:10.3969/j.issn.1000-7377.2024.01.008]
[8]韩海英,郭秀伟,张培彤.川芎对肺癌干细胞原发性肿瘤相关黏附分子影响的实验研究[J].陕西医学杂志,2024,(4):435.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.001]
　HAN Haiying,GUO Xiuwei,ZHANG Peitong.Effect of Rhizoma Chuanxiong on primary tumor-associated adhesion molecules of lung cancer stem cells[J].,2024,(10):435.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.001]
[9]管浩然,闫 冰,李骁扬,等.基于4D-CT的三种呼吸门控技术对肺癌立体定向放射治疗计划靶区及正常组织器官体积、受照剂量的影响[J].陕西医学杂志,2024,(7):926.[doi:DOI:10.3969/j.issn.1000-7377.2024.07.013]
　GUAN Haoran,YAN Bing,LI Xiaoyang,et al.Effects of three respiratory gating techniques based on 4D-CT on planning target volume and the volume and radiation dose of normal tissues and organs in patients undergoing stereotactic body radiotherapy for lung cancer[J].,2024,(10):926.[doi:DOI:10.3969/j.issn.1000-7377.2024.07.013]
[10]薛 昭,陈 治,张 琴.替莫唑胺联合γ-分次立体定向放疗对肺癌脑转移患者血清骨桥蛋白、细胞角蛋白19片段、鳞状细胞癌抗原水平的影响[J].陕西医学杂志,2025,54(4):492.[doi:DOI:10.3969/j.issn.1000-7377.2025.04.011]
　XUE Zhao,CHEN Zhi,ZHANG Qin.Effects of Temozolomide combined with γ-fractionated stereotactic radiotherapy on serum levels of OPN,CYFRA21-1 and SCC in lung cancer patients with brain metastases[J].,2025,54(10):492.[doi:DOI:10.3969/j.issn.1000-7377.2025.04.011]

更新日期/Last Update: 2020-10-10